
Remix launched with a vision to transform patients’ lives through modulation of RNA processing. Our breakthrough science enables the identification of small molecules that influence the expression of disease‑driving mRNAs and proteins. We focus on diseases of high unmet medical need and are committed to operating with scientific rigor and urgency. With a proprietary in‑house technology platform, we have rapidly generated multiple discovery programs advancing toward the clinic. Remix Therapeutics was recognized as one of BioSpace’s Best Places to Work in Boston 2025 and is backed by leading life sciences investors.
Remix Therapeutics is seeking an initiative-taking Associate Director, Strategy & Business Development to support corporate partnering activities and investor communications for a growing private biotechnology company. This individual will play a critical role in shaping strategic opportunities, advancing partnerships, and supporting fundraising efforts while serving as a key interface between scientific, executive, and external stakeholders.
The ideal candidate brings a strong scientific background and 3–5 years of experience in biotech strategy, business development, or life sciences roles. We are seeking someone who thrives in a dynamic environment, demonstrates flexibility in managing priorities, and values in‑person collaboration as this role requires an onsite presence in Watertown, MA.
Key Responsibilities:
Strategy and Business Development
Investor Relations and Financing Support
Qualifications:
Required
Salary Range
$182,160.00 - $222,640.00 USD
This range reflects the expected base salary for this position, plus bonus, equity, and benefits as applicable. Actual salaries may vary based on factors, such as skill, experience, and qualification for the role.

Remix is working to transform patient's lives through modulation of RNA processing and addressing drug targets in diseases of high unmet medical need. We are a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages cutting-edge data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's innovative therapeutic approach led to the discovery of REM-422, a first-in-class RNA processing modulator in oncology, now being evaluated in Phase 1 clinical studies to treat acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (HR-MDS) and adenoid cystic carcinoma (ACC).